Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics Inc (VTGN) is a clinical-stage biopharmaceutical company pioneering neuroscience-focused treatments through innovative stem cell technology. This page provides investors and industry professionals with essential updates on the company’s progress, including press releases, clinical trial milestones, and strategic developments.
Access real-time information on VTGN’s advancements in predictive toxicology, drug metabolism screening, and neuropsychiatric therapies. Our curated news collection ensures you stay informed about regulatory submissions, partnership announcements, and financial disclosures without needing to track multiple sources.
Key updates include progress in stem cell-derived bioassay systems, FDA communications regarding therapeutic candidates, and insights into the company’s unique approach to in vitro testing. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to VTGN’s latest developments. Check back regularly for authoritative reporting on advancements in neuroscience and biotechnology that could shape the future of drug discovery.
VistaGen Therapeutics (NASDAQ: VTGN) announced participation in two investor conferences in March. The first is the Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual Conference from March 17-19, featuring a corporate presentation and a fireside chat on March 19 at 1:00 p.m. ET. The second conference, the Benzinga Biotech Small Cap Conference, is on March 25 at 10:05 a.m. ET. VistaGen aims to develop innovative treatments for anxiety, depression, and central nervous system disorders. More details can be found on the respective conference websites.
VistaGen Therapeutics (NASDAQ: VTGN) has released promising preclinical data for PH10, a Phase 2 investigational pherine nasal spray targeting major depressive disorder (MDD). Unlike traditional antidepressants, PH10's mechanism does not involve GABA-A receptor activation, potentially reducing common side effects. MDD affects over 264 million globally, with the current market dominated by SSRIs and SNRIs, which have slow onset and multiple side effects. With the growing need for effective MDD treatments, PH10 may offer a rapid-onset, stand-alone alternative, addressing concerns raised in FDA communications regarding benzodiazepines.
VistaGen Therapeutics (NASDAQ: VTGN) reported a net loss of $5.65 million for the third quarter of fiscal 2021, down from $6.28 million in the previous year. The company recognized $313,600 in sublicense revenue from its agreement with EverInsight Therapeutics, a significant increase compared to none in the prior year. VistaGen closed a $100 million public offering to strengthen its balance sheet, enabling the launch of pivotal Phase 3 studies for PH94B targeting anxiety disorders, among other clinical trials. Cash and equivalents stood at $104.3 million as of December 31, 2020.
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) has regained compliance with Nasdaq's minimum bid price requirement as of January 5, 2021. The company previously received a notice on January 31, 2020, regarding non-compliance due to a bid price below $1.00 for 30 consecutive business days. VistaGen met the requirement by maintaining a closing bid price of $1.00 or more for 10 consecutive trading days, starting January 4, 2021. VistaGen is now compliant with all Nasdaq listing standards, and the matter is considered closed by Nasdaq.
VistaGen Therapeutics (NASDAQ: VTGN) announced the publication of an article by Dr. Louis Monti and Dr. Michael Liebowitz in CNS Spectrums, detailing the mechanism of action of its investigational neuroactive nasal sprays, PH94B and PH10. These drugs aim to provide rapid-onset treatments for anxiety and depression, respectively, with microgram-level doses designed to avoid the typical side effects of current medications. VistaGen is preparing PH94B for Phase 3 studies and has received Fast Track designation from the FDA.
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) has successfully closed a $100 million public offering, selling 63 million shares of common stock at $0.92 each and 2 million shares of Series D preferred stock at $21.16 each. The Series D shares can convert into common stock pending shareholder approval for a necessary increase in authorized shares. Proceeds will support research, development, and regulatory expenses for CNS drug candidates such as PH94B and AV-101, alongside general corporate needs.
VistaGen Therapeutics (NASDAQ: VTGN) has announced a public offering of 63 million shares of common stock at $0.92 each and 2 million shares of Series D preferred stock at $21.16 each, aiming to raise approximately $100 million. The proceeds will support the development of its CNS drug candidates, including PH94B and PH10, as well as other operational costs. The offering is expected to close by December 22, 2020, pending standard conditions. The securities are registered under a previously filed shelf registration statement with the SEC.
VistaGen Therapeutics (NASDAQ: VTGN) announced a public offering of units comprising common stock and Series D convertible preferred stock. The offering, subject to market conditions, aims to raise capital for research and development of its CNS drug candidates, including PH94B, PH10, and AV-101. The preferred stock can convert into common stock pending stockholder approval to increase authorized shares. The company intends to use the proceeds for ongoing clinical and manufacturing expenses, as well as for general corporate purposes.
VistaGen Therapeutics (NASDAQ: VTGN) announced a significant milestone with the Korean Intellectual Property Office granting a patent for PH10, a nasal spray designed to treat major depressive disorder (MDD). This patent extends protection until at least 2034 and complements existing patents in multiple regions including the U.S. and Europe. CEO Shawn K. Singh emphasized that this patent strengthens their global strategy for PH10, especially as MDD impacts over 264 million adults globally, underscoring the urgent need for innovative treatment options.
VistaGen Therapeutics (NASDAQ: VTGN) has appointed Louis Monti, M.D., Ph.D., as Vice President of Translational Medicine, expanding its R&D team. Dr. Monti has worked with the company since 2018 on drug candidates PH94B and PH10, designed to treat anxiety and depression. PH94B has received FDA Fast Track designation and is preparing for Phase 3 trials for social anxiety disorder (SAD). PH10 is set for Phase 2B development for major depressive disorder (MDD). Both candidates show potential as rapid-onset treatments, which could revolutionize the management of these mental health disorders.
